Study: Many approved cancer drugs lack proof of added benefit

Many cancer drugs approved by the European Medicines Agency (EMA) between 1995 and 2020 lack proof of added benefit, particularly those approved through expedited (“fast track”) pathways, finds a study published by The BMJ today.

NCI funds study to investigate the underlying cellular mechanisms that drive ER+ breast cancer

The National Cancer Institute (NCI) has awarded a 5-year, $2.7 million grant to researchers at Sanford Burnham Prebys to investigate and elucidate the underlying cellular

August 7, 2023

Oxford Vaccine Group launches a pioneering study into human immunity

This study will test the responses of cells in lymph nodes before and after immunization with flu and COVID-19 vaccines and compare reactions in older

October 25, 2023

B-Cell Depletion Helps Maintain Kidney Function in Lupus Nephritis

SAN DIEGO — Treatment with the B-cell depleting agent obinutuzumab (Gazyva) helped patients with lupus nephritis avoid the most serious adverse outcomes, according to a

November 11, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.